Among these, CCL2 has been the most extensively studied, with evidence suggesting its role in inducing drug resistance in breast and CRC cells, underscoring its potential as a diagnostic biomarker and therapeutic target [12,13]. The gene discussed is CCL2; the disease is colorectal carcinoma.